GlaxoSmithkline Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Fourth Quarter and Audited Consolidated and Standalone Earnings Results for the Year, Ended March 31, 2016
May 25, 2016 at 06:05 am EDT
Share
GlaxoSmithkline Pharmaceuticals Limited reported unaudited standalone earnings results for the fourth quarter and audited consolidated and standalone earnings results for the year, ended March 31, 2016. For the quarter, the standalone company reported profit from operations before other income & exceptional items of INR 1,221.9 million against INR 1,210.2 million for the same period of last year. Profit from ordinary activities before tax was INR 1,624.6 million against INR 1,556.9 million for the same period of last year. Net profit from ordinary activities was INR 1,059.8 million or INR 12.5 per basic and diluted share against INR 1,028.5 million or INR 12.1 per basic and diluted share for the same period of last year. Total income from operations (net) was INR 6,929.7 million against INR 6,180.6 million for the same period of last year.
For the year, the standalone company reported profit from operations before other income & exceptional items of INR 4,525.8 million against INR 6,018.4 million for the same period of last year. Profit from ordinary activities before tax was INR 5,770.1 million against INR 7,486.3 million for the same period of last year. Net profit from ordinary activities was INR 3,752.1 million or INR 44.3 per basic and diluted share against INR 4,716.5 million or INR 55.7 per basic and diluted share for the same period of last year. Total income from operations (net) was INR 27,569.6 million against INR 32,875.8 million for the same period of last year.
For the year, the consolidated company reported profit from operations before other income & exceptional items of INR 4,541.0 million against INR 6,076.3 million for the same period of last year. Profit from ordinary activities before tax was INR 5,794.6 million against INR 7,556.8 million for the same period of last year. Net profit from ordinary activities was INR 3,768.2 million or INR 44.5 per basic and diluted share against INR 4,764.1 million or INR 56.2 per basic and diluted share for the same period of last year. Total income from operations (net) was INR 27,683.5 million against INR 33,045.1 million for the same period of last year.
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
GlaxoSmithkline Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Fourth Quarter and Audited Consolidated and Standalone Earnings Results for the Year, Ended March 31, 2016
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED 
